Free tool
FAERS Monitor: Famotidine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219935 or its brand name (Famotidine, Famotidine). Reports on generic versions are filed under their own applications.
Reports
78,942
Serious
53,278
67% of reports
Hospitalization
27,214
Death reported
7,746
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea5,149
- fatigue4,939
- diarrhoea4,819
- off label use4,129
- dyspnoea3,819
- drug ineffective3,758
- chronic kidney disease3,530
- headache3,502
- vomiting3,144
- pain3,086
- dizziness2,919
- acute kidney injury2,806
- death2,721
- pneumonia2,666
- pyrexia2,620
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 678 |
| 2005 | 672 |
| 2006 | 635 |
| 2007 | 628 |
| 2008 | 800 |
| 2009 | 663 |
| 2010 | 963 |
| 2011 | 1,476 |
| 2012 | 1,834 |
| 2013 | 1,084 |
| 2014 | 1,359 |
| 2015 | 2,195 |
| 2016 | 2,700 |
| 2017 | 3,026 |
| 2018 | 4,037 |
| 2019 | 4,683 |
| 2020 | 6,218 |
| 2021 | 6,355 |
| 2022 | 6,923 |
| 2023 | 7,023 |
| 2024 | 8,242 |
| 2025 | 9,224 |
| 2026 | 7,520 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,975,217 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 3,530 | 12.9 | 12.5 | 37,182 |
| acute kidney injurySignal | 2,806 | 5.0 | 4.8 | 8,763 |
| pneumoniaSignal | 2,666 | 2.2 | 2.1 | 1,765 |
| pyrexiaSignal | 2,620 | 2.0 | 2.0 | 1,371 |
| diarrhoea | 4,819 | 2.0 | 1.9 | 2,453 |
| dyspnoea | 3,819 | 1.8 | 1.7 | 1,393 |
| vomiting | 3,144 | 1.8 | 1.7 | 1,106 |
| nausea | 5,149 | 1.7 | 1.7 | 1,666 |
| fatigue | 4,939 | 1.7 | 1.6 | 1,450 |
| dizziness | 2,919 | 1.6 | 1.5 | 601 |
| headache | 3,502 | 1.5 | 1.4 | 580 |
| pain | 3,086 | 1.3 | 1.3 | 273 |
| off label use | 4,129 | 1.3 | 1.2 | 226 |
| death | 2,721 | 0.8 | 0.8 | 85 |
| drug ineffective | 3,758 | 0.8 | 0.7 | 306 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.